Novartis has announced that the FDA has approved Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is...
In a final appraisal, the National Institute of Health and Care Excellence (NICE) decided that data supporting Aimovig are insufficient...
Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval...
In a very unusual move, NICE has reversed its decision made in September 2020, and now recommends the use of Aimovig (erenumab) from Novartis, for migraine prevention treatment.
Novartis has announced that the European Commission (EC) approved Aimovig (erenumab) for the prevention of migraine in adults experiencing four...
Novartis announced the results of two open-label extension studies (OLE) of Aimovig (erenumab) in patients with chronic and episodic migraine,...
Novartis announced that new additional data from the STRIVE Phase III clinical study demonstrates Aimovig (erenumab) 70 mg and 140...
Amgen announced that results reinforcing the long-term safety and efficacy profile of Aimovig (erenumab-aooe) in patients with episodic migraine (EM) are being presented at the Migraine Trust Virtual Symposium.
Novartis announced that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried...
Amgen has announced that it will present new long-term data of Aimovig (erenumab-aooe) across the migraine spectrum at the 2019...